Frequency of aberrant promoter methylation of P15INK4B and O6-methylguanine-DNA methyltransferase genes in B-cell non-hodgkin lymphoma: A pilot study

Archives of Biological Sciences

Volumn 62, Issue 2, 2010, Pages 211-221

  Kurtović, Nada Kraguljac ^b   Krajnović, Milena ^a   Dimitrijevic B ^a   Mihaljević, Biljana ^b   Gotić, Mirjana ^b   Krtolica, Koviljka ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

B cell non Hodgkin lymphoma; Methylation status; O6 methylguanine DNA methyltransferase; P15INK4B

Indexed keywords

EID: 77955148901     PISSN: 03544664     EISSN: None     Source Type: Journal    
DOI: 10.2298/ABS1002211K     Document Type: Article

References (46)

1. Au, W. Y., Fung, A., Man, C., Ma, S. K., Wan, T. S., Liang, R., and Y. L. Kwong (2003). Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. Br. J. Haematol. 120, 1062-1065.
2. INK4A (MTS1) in B-cell and Tcell lymphomas. Blood 94, 1773-1781.
3. Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and J. P. Issa (1998). Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72, 141-196.
4. Baylin, S. B., and J. E. Ohm (2006). Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer. 6, 107-116.
5. Bogdanović, G., Jurišić, V., Kraguljac, N., Mrdjanović, J., Jakimov, P., Krtolica, K., Krajnović, M., Magić, Z., Stojiljković, B., Andrijević, L.j, Srdić, T., Baltić, M., and S. Popović (2007). Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy - related myelodysplastic syndrome. Leuk Res. 31, 1105-1113.
6. Boyum, A. Separation of leucocytes from blood and bone marrow (1968). Scand. J.Clin. Lab. Invest. 21, (suppl. 97), 77-89.
7. INK4B CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood. 94, 2445-2451.
8. Drexler, H. G. (1998). Review of alterations of the cyclindependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 12, 845-859.
9. Hiddemann, W., Dreyling, M., and R.A. Stahel (2005). Minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Onc. 16, i56-i57.
10. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59, 793-797.
11. 6-Methylguanine-DNA Methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 60, 2368-2371.
12. Esteller, M., Corn, P. G., Baylin, S. B, and J. G. Herman (2001).A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225-3229.
13. 6-methylguanine-DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94, 26-32.
14. Esteller, M. (2003). Profiling aberrant methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin. Immunol. 109, 80-88.
15. 6-methylguanine DNA methyltrasferase in human cancer. Oncogene. 23, 1-8.
16. Galm, O., Wilop, S., Luders, C., Jost, E., Gehbauer, G., Herman, J. G., and R. Osieka (2005). Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann. Hematol. 84, 39-46.
17. Galm, O., Herman, J. G., and S. B. Baylin (2006). The fundamental role of epigenetics in hematopoietic malignancies. Blood rev. 29, 1-13.
18. Goelz, S. E., Hamilton, S. R., and B. Vogelstein (1985). Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem. Biophys. Res. Commun. 130, 118-126.
19. Gerson, S. L. (2002). Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 9, 2388-2399.
20. Grunau, C., Clark, S. J., and A. Rosenthal (2001). Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. 29, E65-5.
21. Hanahan, D., and R. A. Weinberg (2000). The Hallmarks of Cancer. Cell. 100, 57-70.
22. Hatta, Y., Hirama, T., Miller, C. W., Yamada, Y., Tomonaga, M., and P. Koeffler (1995). Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult Tcell leukemia. Blood. 85, 2699-2704.
23. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and S. B. Baylin (1996a). Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93, 9821-9826.
24. INK4B. Cancer Res. 56, 722-727.
25. INK4a characterize the major types of hematological malignancies. Cancer Res. 57, 837-841.
26. Houwen, B. (2000). Blood film preparation and staining procedures. Lab. Hematol. 6, 1-7.
27. Jack, A., Barrans, S., Dlythe, D., and A. Rawstron (2005). Demonstration of a germinal center immunophenotype in lymphomas by immunocytochemistry and flow cytometry. In: Methods in Molecular Medicine. (Eds. T. Illidge, and P.W.M. Johnson), 65-91. Humana Press Inc USA.
28. Harris, N.L. (2001). Nature B-cell neoplasms: Introduction. In: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. (Eds. E.S. Jaffe, N.L. Harris, H. Stein, and J.W. Vardiman), 121-126. IARC, Lyon.
29. Jones, P. L., Veenstra, G. J., Wade, P. A., Vermaak, D., Kass, S. U., Landsberger, N., Strouboulis, J., and A. P. Wolffe (1998). Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 23, 62-66.
30. Krtolica, K., Krajnović, M., Ušaj-Knežević, S., Babić, D., Jovanović, D., and B. Dimitrijević (2007). Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value. World J. Gastroenterol. 13, 1187-1194.
31. 6-alkylguanine-DNA alkyltransferase. Carcinogenesis 24, 625-635.
32. INK4B genes as marker of disease in the follow-up of non-Hodgkin's lymphomas. Br. J. Haematol. 109, 97-103.
33. National Cancer Institute (2002). Strategic plan for addressing for the recommendations of the leukemia, lymphoma and myeloma. Progress Review Group 1-60.
34. Paz, M. F., Fraga, M. F., Avila, S., Guo, M., Pollan, M., Herman, J. G., and M. Esteller (2003). A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63, 1114-1121.
35. Rossi, D., Capello, D., Gloghini, A., Franceschetti, S., Paulli, M., Bhatia, K., Saglio, G., Vitolo, U., Pileri, A. S., Esteller, M., Carbone, A., and G. Gaidano (2004). Aberrant promoter methylation of multiple genes throughout the clinicopathologic spectrum of B-cell neoplasia. Haematologica 89, 154-164.
36. Rothe, G., and G. Schmitz (1996). Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia 10, 877-895.
37. Rush, L. J., and C. Plass (2002). Alterations of DNA methylation in hematologic malignancies. Cancer lett. 185, 1-12.
38. nd Ed. (Eds. N. Ford, Ch. Nolan and M. Ferguson), Cold Spring Harbor Laboratory Press, New York.
39. Sangfelt, O., Erickson, S., Heiden, C. J., Gustafsson, A., Einhorn, S., and D. Grander (1999). Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene. 18, 2798-2810.
40. Sherr, C. J., and J. M. Roberts (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes & Dev. 13, 1501-1512.
41. Shi, H., Guo, J., Duff, D. J., Rahmatpanah, F., Chitima-Matsiga, R., Al-Kuhlani, M., Taylor, K. H., Sjahputera, O., Andreski, M., Wooldridge, J. E., and C. W. Caldwell (2007). Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis. 28, 60-70.
42. Stelzer, G. T., Marti, G., Hurley, A., McCoy, P., Lovett, E. J., and A. Schwartz (1997). U.S.-Canadian consensus recommendation on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Standardization and validation of laboratory procedures. Cytometry (Comm. Clin. Cytometry). 30, 214-230.
43. Jaffe, E.S., Harris, N.L., Stein, H., Campo, E., Tileri, S.A., and S.H. Swerdlow (2008). Introduction and overview of the classification of the lymphoid neoplasms. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Eds. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, and J. W. Vardiman), 158-166. IARC, Lyon.
44. Tatsumi, N., van Assendelft, O. W., and K. Naka on Behalf of the ICSH Expert Panel on Cytometry 2002. International Council for Standardization in Haematology (ICSH) Recommendations for Single-Use Evacuated Containers for Blood Specimen Collection for Hematological Analyses. Lab. Hem. 8, 1-6.
45. Verma, M., and S. Srivastava (2002). Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol. 3, 755-763.
46. Visser, K. E., and W. M. Kast (2002). Effects of TGF-β on the immune system: implications for early detection and prevention. Lancet Oncol. 3, 755-763.